American Express Co vs ClearPoint Neuro Inc — how do they compare? American Express Co trades at $345.62 (market cap $230.15B), while ClearPoint Neuro Inc trades at $15.1 (market cap $454.21M). The key difference: American Express Co is far larger — about 506.7× ClearPoint Neuro Inc's market cap, and American Express Co pays a 1.11% dividend while ClearPoint Neuro Inc pays none. Which is the better fit depends on your goals.
| AXP | CLPT | |
|---|---|---|
Market Cap | $230.15B | $454.21M |
Sector | Financials | Health |
52-Week High | $384.82 | $29.60 |
52-Week Low | $292.27 | $8.66 |
Dividend Yield | 1.11% | — |
Enterprise Value | — | $488.79M |
Signals from Pluang's Aura AI — not financial advice
AXP trades at $343.22, up 1.29% today, with a bullish technical signal and strong support at $339. The stock shows robust fundamentals with 2025 revenue of $72.23B and net income of $10.83B, though recent earnings have been mixed. Analyst consensus is a $369.42 price target with 40% buy ratings. Recent news highlights Amex Ventures' AI investments and premium cardmember benefits, reinforcing growth initiatives.
Outlook remains positive due to steady revenue growth and high ROE of 33.97%, but risks include competitive pressures and a P/E of 20.68 above sector averages. The stock offers upside to consensus targets if execution continues, though investors should monitor spending trends and economic sensitivity.
ClearPoint Neuro (CLPT) trades at $15.18, up 4.19% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue growth but missed earnings expectations with a $0.38 loss per share. Despite negative profitability metrics, analyst consensus remains unanimously bullish with 100% buy ratings. Recent news highlights regulatory progress with partners and expansion of the drug delivery ecosystem.
The stock presents a high-risk opportunity with strong analyst support despite current losses. Investment thesis hinges on successful commercialization of neuro drug delivery technologies and partnership execution. Key risks include persistent negative cash flow from operations and delayed revenue ramp-up from new facilities. Upside depends on translating regulatory momentum into sustainable revenue growth.
Trailing returns across standard periods
Latest headlines on both assets
American Express Company is a global payment and travel company. The Company's principal products and services are charge and credit payment card products and travel-related services offered to consumers and businesses around the world.
Read more on AXP →ClearPoint Neuro provides medical devices and software for precise neurosurgical procedures. Its navigation systems allow surgeons to perform minimally invasive brain and spine surgeries with extreme accuracy.
Read more on CLPT →